“百岗校招”的背后：波士顿科学发力房颤赛道

Core Viewpoint - Boston Scientific is accelerating its clinical deployment in the atrial fibrillation (AF) market in China by launching a recruitment plan for clinical technical trainees, indicating a strategic focus on enhancing frontline penetration and support [1][23]. Group 1: Market Observation of Atrial Fibrillation Treatment - Atrial fibrillation (AF) is the most common type of persistent arrhythmia, significantly increasing the risk of stroke and heart failure, with over 12 million patients in China [2]. - Catheter ablation is recognized as the most effective rhythm control method when drug therapy is inadequate, evolving from radiofrequency to cryoablation, and now to pulsed field ablation (PFA) technology [2][3]. - PFA technology offers high-targeted non-thermal ablation, minimizing damage to adjacent structures, and Boston Scientific's FARAPULSE is the first commercially available PFA system [2][3]. Group 2: FARAPULSE System Analysis - The FARAPULSE system is specifically designed for PFA, featuring a closed-loop optimization from energy mechanism to catheter design [4][7]. - It includes a unique catheter structure that enhances electrical field coverage and stability during procedures, with adjustable voltage parameters to ensure effective energy release while minimizing side effects [7][8]. - FARAPULSE is the first commercial catheter system designed from the ground up for PFA, ensuring rapid acceptance and replication by physicians globally [8][9]. Group 3: Global Validation and Innovation - FARAPULSE has the most extensive clinical research support and real-world validation among PFA systems, with over 250,000 patients treated globally by February 2025 [12][10]. - The system is evolving into a platform-type ablation system, enhancing adaptability across different hospital levels and operator skills [14]. - Boston Scientific is advancing its system capabilities towards visualization and platform integration, aiming for broader application in various arrhythmias [13][14]. Group 4: Local Advancement Strategy - FARAPULSE received rapid NMPA registration in China, officially launching in 2024 for treating drug-resistant, recurrent, symptomatic paroxysmal AF [15]. - The company is implementing a comprehensive strategy that includes technical deployment, training, and talent recruitment to build a foundational ecosystem for AF treatment in China [15][23]. - The recruitment of 150 clinical technical support positions across 34 provinces reflects Boston Scientific's commitment to local market development and talent cultivation [1][23]. Group 5: Comprehensive Solution for Atrial Fibrillation - Boston Scientific's FARAPULSE and Watchman systems together form a comprehensive treatment solution for AF, addressing both rhythm control and stroke prevention [19][20]. - The combination of these technologies represents a dual pillar model in AF management, enhancing clinical treatment efficiency and patient outcomes [20][21]. - The integration of these systems is expected to create a synergistic effect, optimizing operational efficiency and patient compliance in clinical settings [26].